本年度很榮幸的,吳醫師在博士班所研究的「利用中藥萃取物誘發肺癌細胞凋亡路徑」的論文被生醫年會接受且發表,這個研究也再度肯定中醫藥在未來或許可以突破許多目前現代醫學治療效果不佳的疾病。
論文摘要如下:
Honokiol induces apoptosis of human lung cancer cells by MKK/p38/p53 pathway and mitochondrial dysfunction
+1Chi-Ming Wu, 2Chien-Lin Wu, 1Te-Mao Li, 1,3Yi-Chin Fong, 4Chih-Hsin Tang
+1School of Chinese Medicine, China Medical University
2Department of Physical Medicine and Rehabilitation, Changhua Christian Hospital
3Department of Orthopaedic Surgery, China Medical University Hospital
4Department of Pharmacology, China Medical University
Lung cancer is the leading cause of cancer-related mortality in both men and women, with 1.2 million new cases diagnosed every year and 1 million deaths being recorded worldwide. In this study, we investigated the anti-cancer effect of a Honokiol, an active component isolated and purified from the Magnolia officinalis in human lung cells. Honokiol-induced cell apoptosis in human lung cancer cell lines (A549 cells) dose-dependently by MTT assay and propidium iodide (PI) assay. Honokial also increased Annexin-V and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) expression. Honokiol induced phosphorylation of MKK3/6, p38 and p53 were also determined. Treatment of Honokiol reduced mitochondria membrane potential. In addition, Honokiol also induced upregulation of Bax and Bak, and downregulation anti-apoptotic Bcl-2 and Bcl-xL expression. Besides, time-dependent cleavage caspases 3 and 9 and increased caspases 3 and 9 activity were also determined by treatment of Honokial in A549 cells. Importantly, animal studies have revealed a dramatic 58% reduction in tumor volume after 21 days of treatment. This study demonstrates that Honokiol may be a novel anti-cancer agent targeting lung cancer cells.
沒有留言:
張貼留言